July 2026 in “Journal of the American Academy of Dermatology” GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.
September 2025 in “Cureus” This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.
May 2024 in “International Journal of Dermatology” This research highlights the lack of clinical evidence linking GLP-1 agonists, commonly used in treating type 2 diabetes and obesity, to hair loss, despite theoretical concerns regarding potential hair health impacts.
59 citations
,
August 2021 in “Frontiers in Endocrinology” This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.